First mover in blood based CNS biomarkers
Disclaimer

This document (the “Presentation”) has been prepared by DiaGenic ASA (the “Company”) exclusively for information purposes. Neither this Presentation nor any copy of it nor the information contained herein is being issued, and nor may this Presentation nor any copy of it nor the information contained herein be distributed directly or indirectly to or into, any jurisdiction in which such distribution would be unlawful or not appropriate. Recipients of the Presentation shall not reproduce, redistribute or pass on, in whole or in part, the Presentation or any of its content to any other person. The Presentation does not constitute, and should not be construed as, an offer to sell or a solicitation of an offer to buy any securities of the Company in any jurisdiction.

This Presentation contains certain forward-looking statements relating to the business, financial performance and results of the Company and/or the industry in which it operates. Forward-looking statements concern future circumstances and results and other statements that are not historical facts, and are sometimes identified by the words “believes”, “expects”, “predicts”, “intends”, “projects”, “plans”, “estimates”, “aims”, “foresees”, “anticipates”, “targets”, and similar expressions. The forward-looking statements contained in this Presentation, including assumptions, opinions and views of the Company or cited from third party sources, are solely opinions and forecasts which are subject to risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements that are expressed or implied by statements and information in the Presentation, including, among others, risks or uncertainties associated with the Company’s business, segments, development, growth management, financing, market acceptance and relations with customers, and, more generally, general economic and business conditions, changes in domestic and foreign laws and regulations, taxes, changes in competition and pricing environments, and fluctuations in currency exchange rates and interest rates. None of the Company or any of its subsidiaries or any such person’s directors, employees or advisors provide any assurance that the assumptions underlying forward-looking statements expressed in this Presentation are free from errors nor does any of them accept any responsibility for the future accuracy of such forward-looking statements.

The information contained in this Presentation has not been independently verified. No representation or warranty (express or implied) is made as to the accuracy or completeness of any information contained herein, and it should not be relied upon as such. None of the Company or its subsidiaries or any such person’s directors, employees or advisors shall have any liability whatsoever arising directly or indirectly from the use of this Presentation. By reading the Presentation, or attending any oral presentation held in relation thereto, you acknowledge that you will be solely responsible for your own assessment of the Company, the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the Company’s business. The content of this Presentation are not to be construed as legal, business, investment or tax advice. Each recipient should consult with its own professional advisors for any such matters and advice.

No action has been taken to allow the distribution of this Presentation in any jurisdictions other than Norway. The Presentation has not been reviewed or registered with, or approved by, any public authority, stock exchange or regulated market. The distribution of this Presentation, as well as any subscription, purchase, sale or transfer of securities issued by the Company, may be restricted by law in certain jurisdictions, and persons into whose possession this Presentation comes are required by the Company to inform themselves about and comply with any such restrictions. Any failure to comply with such restrictions may constitute a violation of the laws of any such jurisdiction. None of the Company or its subsidiary undertakings or any such person’s directors, employees or advisors shall have any responsibility for any such violations.

THIS PRESENTATION AND THE INFORMATION CONTAINED HERIN DO NOT CONSTITUTE AN OFFER OF SECURITIES FOR SALE IN THE UNITED STATES AND ARE NOT FOR PUBLICATION OR DISTRIBUTION TO U.S. PERSONS (WITHIN THE MEANING OF REGULATION S UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”)). THE SECURITIES OF THE COMPANY HAVE NOT AND WILL NOT BE REGISTERED UNDER THE SECURITIES ACT, AND MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED STATES OR TO U.S. PERSONS, EXCEPT PURSUANT TO AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT.

IN RELATION TO THE UNITED KINGDOM, THE PRESENTATION IS STRICTLY CONFIDENTIAL AND IS ONLY DIRECTED AT PERSONS WHO FALL WITHIN THE MEANING OF ARTICLE 19 (INVESTMENT PROFESSIONALS) AND 49 (HIGH NET WORTH COMPANIES, UNINCORPORATED ASSOCIATIONS, ETC.) OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005 OR WHO ARE PERSONS TO WHOM THE PRESENTATION MAY OTHERWISE LAWFULLY BE DISTRIBUTED.

There may have been changes in matters which affect the Company subsequent to the date of this Presentation. Neither the issue nor delivery of this Presentation shall under any circumstance create any implication that the information contained herein is correct as of any time subsequent to the date hereof or that the affairs of the Company have not since changed, and the Company does not intend, and does not assume any obligation, except as required by law, to update or correct any information included in this Presentation.

This Presentation is subject to Norwegian law, and any dispute arising in respect of this Presentation is subject to the exclusive jurisdiction of the Norwegian courts.
DiaGenic – early disease detection in blood

<table>
<thead>
<tr>
<th><strong>Who</strong></th>
<th>Stock listed (OSE:DIAG) life science company based in <strong>Oslo</strong>. Founded in 1998, 20 employees, and holds an extensive portfolio of patents linked to it’s technology and products.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>What</strong></td>
<td>Early diagnosis and blood based biomarkers of devastating diseases. Core focus on Alzheimer’s Disease (<strong>ADtect</strong>®) and early stages thereof (<strong>MCItect</strong>®). Additional product lines in Parkinson’s (<strong>PDtect</strong>®) and Breast Cancer (<strong>BCtect</strong>®).</td>
</tr>
<tr>
<td><strong>Why</strong></td>
<td>Early diagnosis and intervention is key to successful clinical outcome.</td>
</tr>
<tr>
<td><strong>How</strong></td>
<td><strong>Gene expression analysis</strong> from easily available peripheral blood.</td>
</tr>
<tr>
<td><strong>When</strong></td>
<td><strong>ADtect</strong>® and <strong>MCItect</strong>® are currently promoted as biomarkers for pharma and as companion diagnostic opportunities. Multiple partner discussions ongoing with diagnostic and pharma companies. Target FDA submission of <strong>ADtect</strong> in 2013/14 for clinical use in the US.</td>
</tr>
</tbody>
</table>
DiaGenic aim to develop and commercialize products in collaboration with partners

- The business model of DiaGenic:
  - Out-license the Company’s blood based diagnostic portfolio, technology and related IP to recognized global diagnostic players or laboratory chains
  - Enter into R&D collaborations with Pharma and Imaging companies to develop biomarkers and companion diagnostics

- Short term revenues are expected to come from co-development agreements in the form of up-front and milestone payments

- In the medium to long term the goal is to establish sustainable revenue streams from product sales to partners and royalties
Alzheimer’s is a serious public health challenge

- The number of AD patients and associated medical expense is expected to grow exponentially between 2010 and 2050.
- Medicare alone expected to spend $20 trillion on AD between 2010 to 2050 if no advances are made (~40% of total Medicare spending).
- A treatment that delays disease onset by only 5 years will reduce the overall cost of AD by $3.97 trillion over 30 years, a 40% reduction!

The first disease-modifying therapies expected to launch in 2013, and carry a significant price premium:

- Current pricing of Aricept ("gold-standard" symptomatic treatment, but off patent) is $1,000 per year
- Bapineuzumab (Pfizer/J&J) – expected pricing of $6,000 per year, with sales of $2.6 billion in 2019
- Solanezumab (Eli Lilly) - expected pricing of $6,000 per year, with sales of $2.6 billion in 2019
- Gammagard (Baxter) – expected pricing of $30,000 per year, with sales of $1.2 billion in 2019

Datamonitor (Dec 2011) estimates that the Alzheimer’s disease drug market is worth $5.8bn in 2011, forecasted to grow to $14.5bn by 2020
DiaGenic’s concept and core assets - a unique and attractive position in future AD management

- Worlds first gene expression biomarkers for Alzheimer’s Disease
  - ADtect® CE marked in 2009
  - Prodromal AD test under development (MCI.tect®)
  - Concept applicable in other central nervous system ("CNS") disease areas like Parkinson’s disease
- Solid IP in US and Europe for diagnosing AD and stages thereof in blood
- Cooperation with providers of commercially available, quality assured and robust technology platforms for diagnostic use in clinical medicine (Qiagen, Life Technologies)
- Highly experienced team with leading competence in
  - RNA and PCR technologies
  - Bioinformatics
  - Clinical studies and bio banks
  - Industrial development of diagnostic products
- Collaboration with top academic clinics in AD
Development of ADtect® - proven ability to successfully reproduce clinical results

<table>
<thead>
<tr>
<th>Proof of concept</th>
<th>Whole Genome Array</th>
<th>Gene Validation</th>
<th>Prototype</th>
<th>ADtect® Test</th>
</tr>
</thead>
<tbody>
<tr>
<td>Macroarray</td>
<td>Microarray</td>
<td>Real-time PCR</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Membrane 1536 gene probes | AB1700 platform >32000 gene probes | ABI 7900HT 384 gene probes | ABI 7900HT 96 gene probes | ABI 7900HT 96 gene probes |

IPA Stockholm 2005  
AD/PD Salzburg 2007  
Biomarkers Europe Vienna 2007 23 (2011) & ICAD Vienna 2009
In addition to the multitude of genes involved in differentiation, cell cycle and cell metabolism, the ADtect® assays also cover a wide range of known pathways associated with AD pathology, such as Amyloid-beta, pTau, presenilin and mitochondrial processing.
ADtect® multi-center studies – high accuracy achieved

Validation studies indicates a true detection of AD pathology of 85%

- ADtect agreement with clinical diagnosis is 72% (n=412)
  - Clinical diagnosis as set by a review board was used as standard of truth, assumed to be 80% accurate
  - 72% observed agreement with 80% accurate clinical diagnosis indicates a true detection of AD pathology of 85%

- 30 Clinical samples contained CSF biomarker data (Aβ1-42, t-tau, p-tau)
  - 24 of 28 positive CSF samples were correctly predicted with ADtect® (85% agreement)

<table>
<thead>
<tr>
<th>Agreement with clinical diagnosis</th>
<th>Calibration (%)</th>
<th>Validation (%)</th>
<th>Total (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N=208</td>
<td>Initial N=74</td>
<td>Extended N=130</td>
</tr>
<tr>
<td>Overall agreement</td>
<td>71.6</td>
<td>71.6</td>
<td>71.5</td>
</tr>
<tr>
<td>Agreement with positive outcome</td>
<td>71.8</td>
<td>71.9</td>
<td>70.6</td>
</tr>
<tr>
<td>Agreement with negative outcome</td>
<td>71.4</td>
<td>71.4</td>
<td>72.6</td>
</tr>
</tbody>
</table>

ADtect® – Promising opportunities in the current US market

- Promising opportunities in the Alzheimer diagnostic market, despite the limitations of existing treatment options
- ADtect® US sales projection 5 years from launch $150M – 200M, assuming reimbursement and 80% test accuracy

![Graph: US market estimate blood based Alzheimer biomarkers – (USD million)](source: Market survey Destum 2011)
Prodromal AD detection and intervention may increase US AD market by > 60%

“The earlier in the disease process that people at risk for developing Alzheimer's are identified, the sooner we can intervene. Earlier detection will be our best opportunity to prevent continuing damage to the brain, once more effective therapies are developed.”

William Thies, PhD, Chief Medical and Scientific Officer at the Alzheimer’s Association

- Current diagnostics and therapeutic intervention applied at dementia stage
- Successful drug development is expected to significantly boost the AD therapeutic market – increase need and value of diagnostics
- Ability to diagnose and intervene in Prodromal AD may further increase the market significantly

Mild Cognitive Impairment ("MCI")
A heterogeneous syndrome

<table>
<thead>
<tr>
<th>MCI</th>
<th>AD</th>
</tr>
</thead>
<tbody>
<tr>
<td>35%</td>
<td>65%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Year</th>
<th>AD market value, USD billion</th>
<th>MCI market value (USD billion)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2013</td>
<td>4,1 2,9</td>
<td>7,0</td>
</tr>
<tr>
<td>2014</td>
<td>5,7 3,3</td>
<td>9,0</td>
</tr>
<tr>
<td>2015</td>
<td>6,5 4,5</td>
<td>11,0</td>
</tr>
<tr>
<td>2016</td>
<td>7,0 5,0</td>
<td>12,0</td>
</tr>
<tr>
<td>2017</td>
<td>7,8 5,3</td>
<td>13,0</td>
</tr>
</tbody>
</table>

Current diagnostics and therapeutic intervention applied at dementia stage
Successful drug development is expected to significantly boost the AD therapeutic market – increase need and value of diagnostics
Ability to diagnose and intervene in Prodromal AD may further increase the market significantly
Biomarkers for prodromal AD and AD progression identified in collaboration with Pfizer

R&D collaboration with Pfizer

- R&D collaboration with Pfizer entered into in December 2010
- Pilot study to identify gene expression patterns in blood from patients
  - that progress from mild cognitive impairment (MCI) to Alzheimer’s disease
  - with different dementia stages of Alzheimer’s disease
- Compare changes over time in AD patients
  - DiaGenic’s extended gene set from whole genome studies
  - Blood samples from DiaGenic’s clinical studies on MCI patients with validated expert consensus diagnosis
  - Next generation FDA compliant instrumentation (ABI ViiA7)
- Proof of concept established
- Study results reported at the CTAD congress in November 2011

Prodromal AD biomarker identified

- A 20 gene expression signature for prodromal AD identification
  - Stable MCI and MCI converters are discriminated with a 74% accuracy
  - Gene expression demonstrates similar performance as CSF in identifying prodromal AD in an MCI population
- A 113 gene signature in blood for rate of progression in AD
  - Correct staging in >80% of fast progression cases
  - Prediction of AD progression rate with >90% overall agreement in mild AD

<table>
<thead>
<tr>
<th>Model parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sample size</td>
<td>129</td>
</tr>
<tr>
<td>Performance characteristics (results on 66 MCI donors)</td>
<td></td>
</tr>
<tr>
<td>Total prediction accuracy</td>
<td>74%</td>
</tr>
<tr>
<td>Prediction MCI conversion (sensitivity)</td>
<td>74%</td>
</tr>
<tr>
<td>Prediction stable MCI (specificity)</td>
<td>75%</td>
</tr>
</tbody>
</table>
The future of Alzheimer diagnostics as viewed by GE Healthcare

Alzheimer’s Disease ...
... an unmet need for complete Dx solution

Current
- Late disease detection
- Rule Out Other diseases
- Symptomatic drugs
- Clinical follow-up

Future
- Genetic testing
- Blood Test
- Flutemetamol Hippocampal volume (MRI)
- Flutemetamol Amyloid PET
- Vasogenic Oedema (MRI)

Enabling First Generation of Disease Modifying Drugs
The imaging agents described are not approved for use by the FDA or any other health regulatory agency
PDtect® identifies Parkinson patients with high 88% accuracy

- Ongoing DiaGenic European multi-centre study
  - 900 samples from PD patients, controls and patients with related neurologic disorders.
  - 160 denovo patients (early PD without pharmaceutical treatment).
  - Monitored over 2 years for disease progression.

- Overall accuracy across all PD stages using 700 genes was 88%
  - In the diagnostic challenging group of early PD (denovo PD) sensitivity was 85%.
  - Whole genome screen on a subset - 79 PD patients, including 27 denovo PD, and 109 controls
  - >2000 genes impacted by the disease in blood.

- Has generated a substantial interest among several pharmaceutical companies

DiaGenic press release February 8th 2012

Magdalena Kauczynska Karlsson et al.
32nd Annual Conference of the International Society for Clinical Biostatistics 21-25 August 2011 Ottawa, Canada
Several attractive commercial opportunities in the future of AD management

R&D collaborations

Targeted Partners: Pharma Imaging

Prodromal AD Biomarker & CDx

Area of use:

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>R&amp;D Collaboration with Pharma</td>
<td>Pre IDE</td>
<td>CDx development</td>
<td>Revenue stream from</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

PET Enabler

Area of use:

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>R&amp;D Collaboration with Imaging companies</td>
<td>Outlicensing to PET</td>
<td>Signing fee</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Development of Molecular Diagnostics

Targeted Partners: Global Diagnostics Suppliers Laboratory Chains

Prodromal AD MDx Test

Area of use:

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Outlicense Technology Partners</td>
<td>CE marking</td>
<td>FDA PMA</td>
<td>Revenue stream from</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Signing fee</td>
<td>Signing fee</td>
<td>Milestone</td>
<td>MDx Product Revenue US</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
DiAGenic

DiaGenic ASA
Grenseveien 92, N-0663 Oslo, Norway
Tel +47 23 24 89 50
Mail: diagenic@diagenic.com
www.diagenic.com